Skip to main content
Site Search
Close Search

RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Digital PCR

Digital is the new absolute

Who we are

Learn about who we are and what we do to make improvements in life possible.

Join the QIAGEN team

Latest information on COVID-19

News, testing solutions and stories covering global efforts in the fight against COVID-19.

Our stories

Explore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances.

    Market Strategy

    Read our equity story, financial disclosures and how we create shareholder value.

      Latest News

      Read up on our latest press releases or peruse our various media archives.

      Contact Us

      Thank you for choosing QIAGEN. If you have questions about QIAGEN, our products or your order, this page should help you find the answers and contacts you need.

      Overview

      Directors Dealings

      Home  >  Investor Relations  >  Financials & SEC Filings  >  Directors Dealings

      QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy can be downloaded as PDF document here.

      Notes to the overview of recent transactions

      * Cashless Exercise

      1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

      “Net share settlement” is done when a number of shares to cover expenses related to the grant release (such as taxes and transaction costs) are withheld by the Company.

      Recent Transactions

      Name and function Date and type Financial instrument Amount of
      shares      		 SEC BAFin A-FM

      Jonathan M. Pratt

      Chief Executive Officer

      09/01/26

      Grant

       

      Performance Stock Units
      (103,711 units contingent on the achievement of company goals, 69,140 units based on relative total shareholder return)

      172,851

      		 - PDF PDF

      Eva Pisa

      Supervisory Director

      08/11/26

       

      Common Shares withheld (adjustment of February 2026 net share settlement to cover related taxes)

      544

      		- PDF PDF

      Metin Colpan

      Supervisory Director

      06/24/26

       

      Common Shares received through release of Restricted Stock Units (“net share settlement”)

      8,905

      		 - PDF PDF

      Stephen H. Rusckowski,

      Supervisory Director

      05/19/26

      Purchase

      Open market purchase of Common Shares

      29,150

      		 - PDF PDF

      Mark Stevenson,

      Supervisory Director

      05/12/26

      Purchase

      Open market purchase of Common Shares

      60,000

      		- PDF PDF